{"public_id":"cl_a5a1778c1199119b10b3f8cc8c494def","status":"active","superseded_by_public_id":null,"corpus_id":1545777,"text":"Initiating treatment with ropinirole and adding levodopa only if needed reduces the risk of dyskinesia over five years in early Parkinson's disease.","confidence":0.97,"paper":{"corpus_id":1545777,"title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.","url":"https://sah.borca.ai/papers/1545777"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.97,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_441939db84c180c031c67b8d5b1db92e","name":"ropinirole","description":"A dopamine D2-receptor agonist used as an initial treatment for early Parkinson's disease in the study.","types":["drug","dopamine agonist"],"url":"https://sah.borca.ai/concepts/co_441939db84c180c031c67b8d5b1db92e"},{"public_id":"co_7f147b3761f805e93f53fa2230affe8e","name":"levodopa","description":"A dopaminergic medication used as comparator and as supplementary open-label treatment when symptoms were not adequately controlled.","types":["drug","treatment"],"url":"https://sah.borca.ai/concepts/co_7f147b3761f805e93f53fa2230affe8e"},{"public_id":"co_e86cc5156b7391e83a315cb69d957ec3","name":"dyskinesia","description":"Involuntary movement disorder used as the primary outcome measure in the trial.","types":["outcome","adverse effect"],"url":"https://sah.borca.ai/concepts/co_e86cc5156b7391e83a315cb69d957ec3"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_a5a1778c1199119b10b3f8cc8c494def"}